Clinical Trials
14
Active:0
Completed:13
Trial Phases
3 Phases
Early Phase 1:4
Phase 1:8
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (57.1%)Early Phase 1
4 (28.6%)Phase 2
2 (14.3%)Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET
Phase 1
Completed
- Conditions
- Amyotrophic Lateral SclerosisHealthy Volunteers
- Interventions
- Drug: [18F]PBR06
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 23
- Registration Number
- NCT03876002
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03142724
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-03-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03082768
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Early Phase 1
Completed
- Conditions
- Progressive Supranuclear PalsyHealthy VolunteersAlzheimer Disease
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 6
- Registration Number
- NCT03080051
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
Early Phase 1
Completed
- Conditions
- Alzheimer DiseaseHealthy VolunteersProgressive Supranuclear Palsy
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Molecular NeuroImaging
- Target Recruit Count
- 12
- Registration Number
- NCT03058965
- Locations
- 🇺🇸
Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found